Trial Profile
A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single- Ascending Doses of MEDI6012 in Subjects With Stable Coronary Artery Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs MEDI 6012 (Primary) ; MEDI 6012 (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors MedImmune
- 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
- 15 Nov 2017 Results of post-hoc analysis assessing association of intensity of statin therapy and ApoB changes presented at the 90th Annual Scientific Sessions of the American Heart Association
- 08 Nov 2017 According to an AstraZeneca media release, data from the study will be presented at the American Heart Association (AHA) Scientific Sessions 2017.